Market Insights NEWS

AI in pathology is a small but fast-growing market. Size, segments, adoption rates, barriers and the vendors to watch.

The global vaccine market is about $88B in 2026 and growing near 4% a year. Here is where mRNA, advance purchase deals and contract makers are growing faster.

Mobile apps hold about 45% of digital mental health, but wearables and employer-sponsored programs are growing fastest. A look at size, segments and players.

Glycine has quietly become one of the more talked-about ingredients in the sleep supplement world in 2026, and the market data backs up what's showing up in wellness content everywhere. The global glycine market is valued at $1.5 billion in 2026, projected to reach $2.7 billion by 2036, a 6.8% CAGR, with the food and pharmaceuticals industry expected to account for 45.2% market share this year. The narrower glycine supplement sub-segment is growing even faster in percentage t

China's children's nutrition market is producing one of the more counterintuitive growth stories in global consumer health in 2026. Despite birth rates dropping 10% year over year, total sales value of infant and child nutritional supplements increased 33.9% over a recent three-month period, and foreign brands account for a striking 91.5% of market revenue, notably higher than the supplements category overall, where foreign brands hold 68.1%. Fewer Babies, More Spending Per C

GLP-1 weight-loss medications have moved from a pharmaceutical trend to a structural force reshaping what people eat. A spring 2026 survey of 1,007 US adults found roughly 18% are currently using a GLP-1 medication, up from about 14% in 2025, and the 35-54 age cohort leads adoption at 23%. One industry estimate suggests 1 in 2 eligible adults may adopt a GLP-1 drug over the next decade as awareness campaigns build, dosage forms improve, and out-of-pocket costs continue fallin

The preventive healthcare technology market has become one of healthcare's clearest growth stories in 2026. Mordor Intelligence values the global market at $412.59 billion in 2026, up from $366.91 billion in 2025, and projects it will reach $741.85 billion by 2031, a 12.45% CAGR. Other analysts size the category differently depending on scope, Coherent Market Insights puts 2026 at $338.61 billion, SNS Insider at roughly $370 billion, but every major research firm agrees the m

The mRNA platform is proving its post-pandemic staying power. Mordor Intelligence values the global mRNA vaccines and therapeutics market at $74.43 billion in 2026, up from $63.88 billion in 2025, and projects it will reach $159.59 billion by 2031, a 16.5% CAGR. The more important shift isn't the growth rate, it's what the platform is being used for: mRNA is transitioning from an emergency-centric COVID-19 model into a broader therapeutic platform spanning oncology, rare dise

Digital mental health has crossed from early adoption into mainstream infrastructure. The global mental health technology market is estimated at $11.97 billion in 2026, on its way to roughly $56.17 billion by 2035, an 18.74% CAGR, according to Towards Healthcare. A narrower slice of that market, AI-driven mental health tools specifically, is growing even faster: Research and Markets pegs the AI-in-mental-health segment at $2.7 billion in 2026, expanding at a 34.7% CAGR toward

Pharma just got a real-world proof point that AI drug discovery works, and the cost gap is staggering. In February 2026, Insilico Medicine's INS018_055, the first fully AI-designed drug for idiopathic pulmonary fibrosis, completed Phase IIa trials with statistically significant efficacy. It was conceived, designed, and optimized using AI in just 18 months at a computational and discovery cost of roughly $6 million, versus the traditional $100-200 million and 6-8 years typical

Healthcare dealmaking has picked up sharply through the first half of 2026, even as reimbursement pressure, tariff uncertainty, and drug pricing policy continue to create headline risk. Recent midyear outlooks point to a sector that is not pulling back on M&A, but instead getting more selective about where it deploys capital. Biopharma Leads the Charge Biopharma has posted its strongest dealmaking quarter in years, with deal value in the first quarter alone exceeding sixty fi

Artificial intelligence is no longer an experimental add-on in healthcare, it is quickly becoming core infrastructure. From diagnostic imaging to hospital operations, AI-driven tools are reshaping how care is delivered, priced, and scaled. Here is what is driving the market in 2026, and where the opportunities lie for investors, health systems, and technology vendors. Why the AI Healthcare Market Is Accelerating Three forces are converging to push adoption faster than earlier

The Future of Healthcare: Trends, Challenges, and Opportunities Executive Summary The healthcare industry is undergoing a significant...

LabGenomics USA, a subsidiary of South Korea’s LabGenomics, has been strategically expanding its footprint in the U.S. diagnostics...

Fabric, a leader in healthcare technology, has announced its acquisition of TeamHealth VirtualCare, a nationwide virtual care provider...